Skip to content

For US Healthcare Professionals Only

Prescribing Information
Patient Site
VEVYEContact Us

Take theFast TrackTo Dry Eye Disease Relief*

VEVYE® (cyclosporine ophthalmic solution) 0.1% is the first and only semifluorinated alkane dissolved cyclosporine for the treatment of the signs and symptoms of dry eye disease.1-3

A VEVYE carton and bottle
A VEVYE carton and bottle

Take theFast TrackTo Dry Eye Disease Relief*

VEVYE® (cyclosporine ophthalmic solution) 0.1% is the first and only semifluorinated alkane dissolved cyclosporine for the treatment of the signs and symptoms of dry eye disease.1-3

A Trusted Active

Transformed Through the Vehicle

Improved Bioavailability4

Perfluorobutylpentane delivered ~22x more cyclosporine into the cornea vs. Restasis® (cyclosporine ophthalmic solution) 0.05%.**

Explore Vehicle

*Rapid Onset5-6

In clinical studies, VEVYE demonstrated clinically meaningful and statistically significant improvement in total corneal fluorescein staining by Day 15.

Review Studies

Well-Tolerated5-7

In clinical studies, 99.8% of patients experienced no or mild instillation site pain.

See Safety

Improved Bioavailability4

Perfluorobutylpentane delivered ~22x more cyclosporine into the cornea vs. Restasis® (cyclosporine ophthalmic solution) 0.05%.**

Explore Vehicle

*Rapid Onset5-6

In clinical studies, VEVYE demonstrated clinically meaningful and statistically significant improvement in total corneal fluorescein staining by Day 15.

Review Studies

Well-Tolerated5-7

In clinical studies, 99.8% of patients experienced no or mild instillation site pain.

See Safety

**Clinical relevance not yet established.

See Vevye InAction

When it comes to a drop, less is more1

No Water

No Preservatives

No pH

No Osmolarity

Explore the Studies

Preclinical

Results

See the Data

Phase 2

Head-to-head

See The Data

Phase 3

Results

See The Data

Long-term

Results

See The Data
    The VEVYE savings card

    Access For All Patients

    • Eligible commercial patients may receive their first prescription for as little as $0†

      Eligible commercial patients may receive their first prescription for as little as $0†

    • The Savings Program may reduce your patient's prescription cost†

      The Savings Program may reduce your patient's prescription cost†

    Learn More
    The VEVYE savings card

    †For patients whose prescriptions are covered by commercial insurance, use of this program may reduce your copayment so that you may pay as little as $0. For patients whose prescriptions are not covered by commercial insurance use of this program may reduce your cost for prescriptions to as little as $59. For full terms and conditions, please visit getvevye.com.

    INDICATION AND USAGE

    VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

    IMPORTANT SAFETY INFORMATION

    Warnings and Precautions

    • Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
    • Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

    Adverse Reactions

    In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about VEVYE, please see the Full Prescribing Information.

    INDICATION AND USAGE

    VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

    IMPORTANT SAFETY INFORMATION

    Warnings and Precautions

    • Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
    • Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

    Adverse Reactions

    In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

    For additional information about VEVYE, please see the Full Prescribing Information.

    IMPORTANT SAFETY INFORMATION

    Warnings and Precautions

    • Potential for Eye Injury and Contamination – Patients should not touch the bottle tip to the eye or other surfaces.
    • Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If worn, lenses should be removed prior to administration and may be reinserted 15 minutes following the administration of VEVYE.

    IMPORTANT SAFETY INFORMATION

    Warnings and Precautions

    • Potential for Eye Injury and Contamination – Patients should not touch the bottle tip to the eye or other surfaces.